Department of Pediatrics, Fukushima Medical University School of Medicine, Fukushima, Japan.
Pediatr Blood Cancer. 2014 Oct;61(10):1880-2. doi: 10.1002/pbc.24962. Epub 2014 Jan 25.
Myeloid/natural killer cell precursor acute leukemia (MNKL) is an aggressive disease with a high relapse rate even after allogeneic hematopoietic stem cell transplantation (SCT). We report a patient with MNKL who had a donor lymphocyte infusion (DLI) for relapse after T cell-replete human leukocyte antigen (HLA)-haploidentical SCT, but relapsed again 20 months later with loss of mismatched HLA. This case suggests that a strong graft-versus-leukemia effect of haploidentical SCT can be expected in MNKL patients. In the haploidentical setting, DLI should be considered for patients with relapsed leukemia whose leukemic cells have not lost HLA cell surface expression.
髓系/自然杀伤细胞前体细胞急性白血病(MNKL)是一种侵袭性疾病,即使在异基因造血干细胞移植(SCT)后,复发率也很高。我们报告了一例 MNKL 患者,在 T 细胞完全人白细胞抗原(HLA)-单倍体相合 SCT 后因复发接受供者淋巴细胞输注(DLI),但 20 个月后再次复发,失去了错配 HLA。该病例提示单倍体相合 SCT 对 MNKL 患者可能有较强的移植物抗白血病效应。在单倍体相合的情况下,对于白血病细胞尚未丧失 HLA 细胞表面表达的复发白血病患者,应考虑 DLI。